Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2 publications
Biosimilars and the extrapolation of indications for inflammatory conditions.
Journal: Biologics : targets & therapy
Published: March 04, 2017
Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase.
Journal: Annals of the rheumatic diseases
Published: June 29, 2014
Showing 1-2 of 2
Last Updated: 09/26/2026